Advertisement
U.S. markets open in 5 hours 14 minutes
  • S&P Futures

    5,303.75
    -4.50 (-0.08%)
     
  • Dow Futures

    40,094.00
    -50.00 (-0.12%)
     
  • Nasdaq Futures

    18,491.50
    -12.25 (-0.07%)
     
  • Russell 2000 Futures

    2,133.80
    -4.60 (-0.22%)
     
  • Crude Oil

    81.86
    +0.51 (+0.63%)
     
  • Gold

    2,212.00
    -0.70 (-0.03%)
     
  • Silver

    24.55
    -0.21 (-0.84%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.94
    +0.16 (+1.25%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • USD/JPY

    151.4040
    +0.1580 (+0.10%)
     
  • Bitcoin USD

    70,410.02
    +491.00 (+0.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,950.89
    +18.91 (+0.24%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Stemline Therapeutics, Inc. (STML)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Stemline Therapeutics, Inc. (STML) in connection with the proposed acquisition of the company by A. Menarini-Industrie Farmaceutiche Riunite - S.r.l., a privately-held pharmaceutical company based in Italy. Under the terms of the acquisition agreement, STML shareholders will receive $11.50 in cash and a contingent value right purportedly valued at $1.00 for each STML share that they own. If you own STML shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/stemline-therapeutics-inc/

Portola Pharmaceuticals, Inc. (PTLA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Portola Pharmaceuticals, Inc. (PTLA) in connection with the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. (“ALXN”). Under the terms of the acquisition agreement, PTLA shareholders will receive $18.00 for each share of PTLA that they own. If you own PTLA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/portola-pharmaceuticals-inc-ii/

Quintana Energy Services, Inc. (QES)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Quintana Energy Services, Inc. (QES) in connection with the proposed acquisition of the company by KLX Energy Services Holdings, Inc. (“KLXE”). Under the terms of the acquisition agreement, QES shareholders will receive 0.4844 shares of KLXE common stock for each QES share that they own, representing implied per-share merger consideration of approximately $0.75 based upon KLXE’s May 20, 2020 closing price of $1.54. If you own QES shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/quintana-energy-services-inc/

Advertisement